Status:
TERMINATED
TXA and Corona Virus 2019 (COVID19) in Outpatients
Lead Sponsor:
University of Alabama at Birmingham
Conditions:
COVID-19
Eligibility:
All Genders
19+ years
Phase:
PHASE2
Brief Summary
A controlled trial of the drug tranexamic acid (TXA) in outpatients who were recently diagnosed with COVID-19. It is hypothesized that TXA will reduce the infectivity and virulence of the virus.
Detailed Description
A recent report in Physiological Reviews proposed that the endogenous protease plasmin acts on the COVID19 virus by cleaving a newly inserted furin site in the S protein portion of the virus resulting...
Eligibility Criteria
Inclusion
- Positive COVID-19 test
- Outpatient
- Age \>/= 19 y.o.
Exclusion
- Allergic reaction to tranexamic acid
- History of hypercoagulation disorders (deep venous thrombosis, pulmonary thromboembolism)
- Ongoing anticoagulation
- History of GI bleeding
- History of Seizures
- Cardiac or other vascular stents
- History of severe renal disease
- History of intracranial hemorrhage
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 21 2021
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04338074
Start Date
June 1 2020
End Date
April 21 2021
Last Update
May 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35222